Literature DB >> 16804123

A priori dietary omega-3 lipid supplementation results in local pancreatic macrophage and pulmonary inflammatory response attenuation in a model of experimental acute edematous pancreatitis (AEP).

Suhail Sharif1, Michael Broman, Tricia Babcock, Evan Ong, David Jho, Marek Rudnicki, W Scott Helton, N Joseph Espat.   

Abstract

BACKGROUND: Acute pancreatitis is often complicated by multiorgan dysfunction, which is postulated to occur in part by macrophage infiltration into the pancreas. Eicosapentaenoic acid (EPA), an omega-3 fatty acid, is the principal biologic component of fish oil and has clinically and experimentally been demonstrated to be anti-inflammatory. We hypothesized that dietary EPA supplementation before the induction of pancreatitis would attenuate both M-mediated local pancreatic and systemic pulmonary inflammatory response in an in vivo model of acute edematous pancreatitis (AEP).
METHODS: Male Sprague-Dawley (SD) rats were pretreated 2 times per day with oral gavage with EPA (omega-3 fatty acid; 5 mg/kg/dose) or omega-6 fatty acid control (5 mg/kg/dose) or saline (equal volume) for 2 weeks. AEP was induced in omega-3, omega-6, and saline pretreated rats by 5 hourly subcutaneous (SC) injections of cerulein. Pancreas, lung, and serum were harvested 3 hours after the last cerulein injection. Severity of pancreatitis was confirmed by serum amylase and by histopathologic score. Pancreatic macrophage infiltration was assessed by confocal fluorescent microscopy, and pulmonary leukocyte respiratory burst (LRB) analysis was performed on mononuclear cells obtained from bronchioalveolar lavage (BAL).
RESULTS: All animals demonstrated acute pancreatitis through hyperamylasemia and histopathologic examination. Confocal analysis demonstrated significantly lower macrophage infiltration, and BAL analysis by flow cytometry demonstrated significantly lower (p < .05) LRB in the omega-3-treated group compared with the omega-6 and the saline pancreatitis group.
CONCLUSIONS: Attenuation of both pancreatic MPhi inflammatory response and pulmonary leukocyte respiratory burst in AEP by EPA supports further investigation into the potential role for EPA dietary supplementation in the progression of pancreatitis-associated sequelae.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16804123     DOI: 10.1177/0148607106030004271

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  6 in total

1.  Acute pancreatitis in obesity: adipokines and dietary fish oil.

Authors:  Hayder H Al-Azzawi; Terence E Wade; Deborah A Swartz-Basile; Sue Wang; Henry A Pitt; Nicholas J Zyromski
Journal:  Dig Dis Sci       Date:  2011-02-24       Impact factor: 3.199

2.  Effect of dietary fats on oxidative-antioxidative status of blood in rats.

Authors:  Anna Walczewska; Barbara Dziedzic; Tomasz Stepien; Elzbieta Swiatek; Dariusz Nowak
Journal:  J Clin Biochem Nutr       Date:  2010-04-23       Impact factor: 3.114

Review 3.  Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer.

Authors:  Lorne J Hofseth
Journal:  Cancer Lett       Date:  2008-04-25       Impact factor: 8.679

4.  Reduction of inflammation and chronic tissue damage by omega-3 fatty acids in fat-1 transgenic mice with pancreatitis.

Authors:  Karsten H Weylandt; Anja Nadolny; Lena Kahlke; Thomas Köhnke; Christoph Schmöcker; Jingdong Wang; Gregory Y Lauwers; Jonathan N Glickman; Jing X Kang
Journal:  Biochim Biophys Acta       Date:  2008-09-12

5.  Eicosapentaenoic acid suppresses ocular inflammation in endotoxin-induced uveitis.

Authors:  Misa Suzuki; Kousuke Noda; Shunsuke Kubota; Manabu Hirasawa; Yoko Ozawa; Kazuo Tsubota; Nobuhisa Mizuki; Susumu Ishida
Journal:  Mol Vis       Date:  2010-07-17       Impact factor: 2.367

6.  Efficacy of thymosin α1 and interferon α for the treatment of severe acute pancreatitis in a rat model.

Authors:  Xiaoqin Wang; Xiaoyan Zeng; Bo Yang; Shan Zhao; Wei Chen; Xuan Guo
Journal:  Mol Med Rep       Date:  2015-09-01       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.